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Abstract
Background: Colorectal surgery is frequently complicated by surgical site infections (SSIs). The most important
consequences of SSIs are prolonged hospitalization, an increased risk of surgical reintervention and an increase in
mortality. Perioperative intravenously administered antibiotic prophylaxis is the standard of care to reduce the risk
of SSIs. In the last few decades, preoperative orally administered antibiotics have been suggested as additional
prophylaxis to further reduce the risk of infection, but are currently not part of routine practice in most hospitals.
The objective of this study is to evaluate the efficacy of a preoperative orally administered antibiotic prophylaxis
(Pre-OP) in addition to intravenously administered perioperative antibiotic prophylaxis to reduce the incidence of
deep SSIs and/or mortality after elective colorectal surgery.
Methods/design: The PreCaution trial is designed as a multicenter, double-blind, randomized, placebo-controlled
clinical trial that will be carried out in The Netherlands. Adult patients who are scheduled for elective colorectal
surgery are eligible to participate. In total, 966 patients will be randomized to receive the study medication. This will
either be Pre-OP, a solution that consists of tobramycin and colistin sulphate, or a placebo solution. The study
medication will be administered four times daily during the 3 days prior to surgery. Perioperative intravenously
administered antibiotic prophylaxis will be administered to all patients in accordance with national infection control
guidelines. The primary endpoint of the study is the cumulative incidence of deep SSIs and/or mortality within
30 days after surgery. Secondary endpoints include both infectious and non-infectious complications of colorectal
surgery, and will be evaluated 30 days and/or 6 months after surgery.
Discussion: To date, conclusive evidence on the added value of preoperative orally administered antibiotic prophylaxis
in colorectal surgery is lacking. The PreCaution trial should determine the effects of orally administered antibiotics in
preventing infectious complications in elective colorectal surgery.
Trial registration: Netherlands Trial Register, ID: NTR6113. Registered on 11 October 2016; EudraCT 2015-005736-17.
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Background
Surgical site infections (SSIs) are the most common
hospital-acquired infections in surgical patients [1, 2].
SSIs are associated with extended hospitalization and are
an important source of readmissions and surgical rein-
tervention [2–4]. Relative to other surgical procedures,
the incidence of SSIs is highest after colorectal resec-
tions, affecting up to 15% of all patients [5]. Despite
extensive efforts that have been made in improving
infection control practice, the incidence of SSIs after
colorectal surgery remains unaffectedly high, whereas
the incidence appears to have declined in other surgical
specialties [6]. This persisting infection rate highlights
the need to explore novel measures to reduce SSIs after
colorectal procedures.
To establish new infection prevention measures, it is
important to understand the pathogenesis of SSIs. The
development of these infections is preceded by microbial
contamination of the surgical site [7]. The colon and
rectum are densely colonized by microorganisms which
explains the high postoperative infection rate [8, 9], as
well as the finding that the microorganisms that are
most frequently isolated from colorectal SSIs are also
the colonizing species [10–12].
An important measure to reduce the risk of postopera-
tive infections is to intravenously administer periopera-
tive prophylactic antibiotics that cover these species,
conforming to the national infection control guidelines
[13]. For colorectal surgery, orally administered antibi-
otics can be applied in addition to the intravenously ad-
ministered prophylaxis. This prophylaxis contains non-
absorbable antibiotics, such as neomycin combined with
erythromycin or metronidazole, that are administered 1
to 2 days prior to the surgical procedure. The non-
absorbable nature of these antibiotics implies almost
complete absence of systemic uptake after oral intake.
The antibiotics, therefore, only exert local activity in the
gastrointestinal tract with low risks of side effects. The
rationale of combining systemic and oral prophylaxis is
that orally administered antibiotics reduce the colonic
bacterial contamination levels directly at the surgical
site, whereas systemic antibiotics are used as a safeguard
by establishing effective antibiotic concentrations in the
soft tissues to minimize the risk of infection and to pre-
vent perioperative endotoxinemia. Despite the beneficial
effects of the addition of orally to intravenously adminis-
tered prophylaxis in preventing infections in individual
studies, the oral administration of antibiotics is currently
not recommended in international infection control
guidelines because of large variability in the antibiotic
regimens tested and the limited availability of high-
quality studies [14].
The oral administration of antibiotics to reduce the co-
lonic bacterial load became popular as surgical prophylaxis
for colorectal surgery in the 1970s [8]. At that time it was
believed that orally administered antibiotics would only be
effective when the colon was simultaneously cleansed of its
contents. Therefore, mechanical bowel preparation (MBP),
a technique that involves the administration of osmotic
substances to induce voiding of the intestinal contents, was
introduced and combined with the preoperative oral
administration of antibiotics [9, 15] This combination be-
came standard of care in colorectal surgery. Since then, sev-
eral studies have questioned the necessity and safety of
MBP [15, 16]. Recent meta-analyses have concluded that
the use of MBP prior to colorectal surgery could be safely
omitted, as MBP alone had no overall beneficial effect on
postoperative complications and caused substantial discom-
fort for the patient [17–21]. Furthermore, MBP has been
associated with an increase in inflammatory processes, or
with spillage of liquid bowel contents when bowel prepar-
ation was performed inadequately resulting in an increase
in postoperative infections [16, 22]. Therefore, MBP is no
longer recommended in the international guidelines
for colorectal surgery. The practice of MBP was also
abandoned as the pre-surgical admission period has
continuously decreased, precluding these preoperative
preparations. The oral administration of antibiotics in
an uncleansed colon was thought to be ineffective,
resulting in the simultaneous disappearance of oral
bowel cleansing and orally administered antibiotic
prophylaxis [23].
A recent Dutch single-center, randomized, placebo-
controlled trial (RCT) provided new insights into the
use of orally administered antibiotics as a surgical
prophylaxis prior to gastrointestinal surgery [24]. Instead
of using the common regimens for orally administered
prophylaxis consisting of tablets, the efficacy of a com-
bination of non-absorbable antibiotics in a suspension
was investigated. This suspension contained tobramycin,
colistin and amphotericin B and is also used in selective
decontamination of the digestive tract (SDD), an infec-
tion control measure implemented on intensive care
units (ICUs). This study reported a 36% reduction of the
incidence of infectious complications and anastomotic
leakage in patients receiving the preoperative antibiotic
prophylaxis. However, the study included patients who
underwent all types of gastrointestinal procedures (N =
294). Colorectal procedures were analyzed as a sub-
group, resulting in limited statistical power. Further-
more, MBP was frequently administered to patients
undergoing colorectal procedures. Nevertheless, the re-
sults of this study are promising and encourage further
research to confirm the benefit of using orally adminis-
tered prophylaxis.
In conclusion, the high incidence of SSIs after colorec-
tal surgery and its associated morbidity and mortality
justifies the evaluation of new preventive approaches.
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Preoperative orally administered antibiotic prophylaxis,
in addition to standard perioperative intravenously
administered prophylaxis, may reduce the incidence of
SSIs after colorectal surgery. However, data on its effi-
cacy without the concurrent practice of MBP are lacking
[25]. A randomized, double-blind, placebo-controlled
clinical trial is, therefore, warranted.
Methods/design
Study hypothesis and objectives
The objective of this trial is to determine the efficacy of
preoperative orally administered antibiotic prophylaxis
(Pre-OP) in addition to perioperative intravenously
administered antibiotic prophylaxis on the incidence of
deep SSIs and/or mortality after elective colorectal sur-
gery. We hypothesize that Pre-OP will result in a relative
reduction of the risk of deep SSIs and/or mortality of at
least 40%.
Study design and setting
The PreCaution study is designed as a double-blind, ran-
domized, placebo-controlled, multicenter trial. The study
will be conducted in Dutch university and non-
university hospitals. Study centers will be eligible to par-
ticipate in the study if antibiotic prophylaxis other than
the perioperative intravenously administered prophylaxis
is not part of the standard perioperative care for colorec-
tal surgery. Patient enrollment started in April of 2017
and is expected to be completed within 18 months after
the start of the study.
Study population
Eligibility criteria
Participants will be drawn from a population of adult
patients who will undergo elective colorectal surgery.
Patients with an absolute contraindication for the study
medication, such as pregnant women or nursing
mothers, patients with a previously diagnosed allergy for
the antibiotics in the study medication or patients with
myasthenia gravis, are excluded from participation.
Inclusion and exclusion criteria are presented in Table 1.
Sample size
The sample size is calculated to be 966 patients, based
on a one-sided type I error of 2.5%, a type II error of
20% and an assumed 40% reduction on the absolute risk
for the primary outcome in the intervention group.
The absolute risk of the primary outcome is assumed to
be 14%. Furthermore, one interim analysis will be con-
ducted halfway using O’Brien-Fleming type of boundar-
ies, with the possibility of stopping the trial for efficacy
in case of overwhelming treatment effect. The absolute
risk and the 40% relative risk reduction based on unpub-
lished data from a 4-year survey of a Dutch teaching
hospital, where identical preoperative orally adminis-
tered antibiotic prophylaxis was introduced as standard
of care.
Evaluable patients
Patients who start with the 3-day intervention period
but for whom surgery is cancelled or postponed for
more than 7 days, will not be evaluable for analysis of
the primary and secondary outcomes. Sample size calcu-
lations are based on evaluable patients and, herewith,
assumes replacement of all non-evaluable patients. A
limit of 7 days is chosen as a cut-off to ensure that
patients are not re-colonized at the time of surgery,
since it is expected that the effects of decontamination
will last for a least several days when the 3-day treat-
ment course is completed.
Assignment of interventions
Randomization
After enrollment, patients will be randomly assigned to
one of two treatment arms in a 1:1 ratio.
The randomization will be performed using a per-
muted block design with varying block sizes and stratifi-
cation per study center. An independent pharmacist
form Stichting Apotheek Haarlemse Ziekenhuizen, who
will also be in charge of the production of the study
medication, will perform the randomization. The phar-
macy will provide the study medication in identical con-
tainers that will be sequentially numbered with unique
medication numbers. These numbers will correspond to
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Adult patients undergoing elective colorectal surgery Age < 18 years
Legally incapacitated patients
Patients who are unable to sign informed consent
Patients who have an inability to take medication orally
Patients who have undergone abdominal surgery within 30 days before randomization
Patients with a documented allergy to colistin or aminoglycoside antibiotics
Pregnant women or nursing mothers
Patients diagnosed with myasthenia gravis
Patients with a pre-existent stoma
Patients who previously participated in the PreCaution trial or patients who already
received study medication but for whom surgery was postponed for more than 7 days
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the treatment allocation, and will be documented on the
allocation list. This list will be guarded by the hospital
pharmacist of the Amphia Hospital (Breda, The
Netherlands) who will coordinate the distribution of the
study medication to the study centers. Members of the
local study teams will be instructed to distribute the
study medication according to the allocation sequence.
The unique study medication identification numbers will
be linked to the subjects at enrollment on a subject
identification log.
Blinding
Patients, treating physicians and individuals assessing
the study outcomes will be blinded to the treatment
assignments for the duration of the study. Treatment
assignments will be revealed when all patients have com-
pleted their 6-month follow-up period.
Individual unblinding will be considered only when
the treating physician deems knowledge of the treatment
assignment essential for the safety of the patient. Any
intentional or unintentional breaking of the blinding will
be reported to the sponsor.
Treatment of subjects
Intervention
All patients will receive the study medication as part of
the intervention. The intervention can either be treat-
ment with active medication (Pre-OP) or a placebo. Pre-
OP is a transparent solution that consists of two anti-
biotic components: colistin sulphate (20 mg/mL) and
tobramycin (16 mg/mL). Placebos are manufactured
without the active antibiotic components. The placebo
solutions contain flavoring additives and colorants to
mimic the taste and color of Pre-OP. All patients will
receive perioperative intravenously administered prophy-
laxis according to the national infection prevention
guidelines [26].
Dosage and route of administration
Patients are instructed to take the study medication four
times daily, during the last 3 days prior to surgery. Each
dose consists of 5 mL of either Pre-OP or placebo. In
the case of Pre-OP, this represents 100 mg of colistin
sulphate and 80 mg of tobramycin.
Outcome measures
As a primary composite endpoint, we will investigate the
efficacy of Pre-OP on deep SSI and/or mortality within
30 days after surgery. The secondary endpoints including
their definitions are summarized in Table 2.
Assessment and follow-up
Study procedures
The study procedures are listed in Table 3. The pre-
operative study procedures will take place during visits
to the outpatient clinic. These visits will be routinely
scheduled and will not be planned as study-specific pro-
cedures. During the first visit, the trial will be explained
and patients will receive an information letter. Informed
consent will be signed during a second preoperative
visit. During this visit, the study medication will be pro-
vided along with instructions for use and a study diary.
Furthermore, the first rectal swab will be taken and pa-
tients will receive the first quality-of-life questionnaire.
The study diary will be used to document the intake of
study medication and to report potential side effects due
to the study medication. Patients will take the study
medication according to the instructions during the
3 days prior to surgery. The bottles with remainders of
study medication will be collected at hospital admission
and will be weighted to estimate treatment adherence.
The study diaries will also be collected at admission.
Patients will be followed until 6 months after surgery
to evaluate the development of primary and secondary
outcomes. The data on almost all of these outcomes,
including infectious complications will be documented
as part of daily practice. Thirty days after surgery, the
medical records will be assessed to collect data on pri-
mary and secondary outcomes and a second rectal swab
will be taken by either the patient or by a member of the
local study team. Six months after surgery, the medical
records will be assessed again to collect additional data
on readmissions and length of hospital stay, including
admissions to the ICU. Furthermore, patients will
receive the second quality-of-life questionnaire. After
the questionnaire has been completed and sent back to
the study team, the follow-up is completed.
Retention and withdrawal of participants
Patients are free to withdraw from the study at any time,
which is in accordance with the Dutch law on medical
research on humans. When patients are unwilling to
have the rectal swab taken or to fill in the questionnaire,
these data will considered to be missing and will be dealt
with in data analysis using the appropriate methods.
The intention-to-treat principle will be applied to our
primary analysis to deal with poor or non-compliance to
the study medication, as this is likely to reflect daily
practice. The remainders of study medication will be
weighted to estimate the compliance. To enhance the
compliance, patients are informed about the bitter taste
of the treatment and are advised to take the study medi-
cation together with other drinks to mask the taste.
Another strategy that will be applied to enhance reten-
tion of patients is to call the patients on the two
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postoperative follow-up moments to remind them about
the rectal swab requirement and the questionnaire that
will be send to their home address.
Microbiological methods
Clinical cultures will be performed and processed in the
local microbiology laboratory of the participating centers
according to the routine laboratory procedures. Date of
culture, specimen type, species cultured, antimicrobial
susceptibility and the production of extended-spectrum
beta-lactamase or carbapenemase will be documented.
Fecal samples from patients who develop nosocomial diar-
rhea will be tested for the presence of Clostridium difficile
toxins, according to routine laboratory procedures and
based on the indication by the attending physician.
Rectal swabs will be pre-enriched and subsequently
cultured using selective media, aimed at the detection of
extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae and carbapenem-, tobramycin- and
colistin-resistant, Gram-negative bacterial species’ iden-
tification and antimicrobial susceptibility testing will be
performed for all isolates that grow on either one of the
screening agars. Phenotypic ESBL confirmation will be
performed with the combination disk diffusion method
according to the NVMM guideline on the laboratory
detection of highly resistant microorganisms (HRMO).
Data management
An electronic Case Report Form (eCRF) will be used for
each patient to collect all data on baseline patient char-
acteristics and outcomes (Additional file 1). The data
management department of the Julius Center for Health
Sciences and Primary care at the UMC Utrecht devel-
oped the eCRF which is hosted by ResearchOnline.
Patients will receive a unique identification number at
inclusion. The list with the unique identification num-
bers linked to the patient will be securely stored at the
study site where the patient is included. This list will be
the only way to trace the identification numbers back to
the individual patients. When the data are entered in the
eCRF, patients will be identified with the unique identifi-
cation number. No patient numbers, names, addresses
or complete dates of birth will be recorded.
Table 2 Definition of endpoints
Endpoints Definitions
Primary composite endpoint
Cumulative incidence of deep surgical site infection
and/or mortality within 30 days after surgery
Deep SSI will be diagnosed according to the CDC criteria for surgical site infections [37].
Deep SSI includes both deep incisional SSI and organ/space SSI
Secondary endpoints
30 days after surgery
Cumulative incidence of superficial SSI Superficial and deep SSIs will diagnosed according to the CDC criteria for surgical site
infections [37]
Cumulative incidence of deep SSI
All-cause mortality
Cumulative incidence of bacteremia Blood cultures positive for microorganisms
Cumulative incidence of infection with Clostridium
difficile
Stool sample positive for C. difficile toxins
Cumulative incidence of infection with HRE Clinical cultures positive for ESBL or carbapenemase-producing Enterobacteriaceae or
Enterobacteriaceae resistant to quinolones and/or aminoglycosides [38]
Cumulative incidence of rectal colonization with
HRE and colistin resistant species
Rectal swabs positive for HRE or colistin resistant species, measured at baseline and
30 days after surgery
Cumulative incidence of anastomotic leakage Clinical and/or radiological evidence of leakage requiring surgical or radiological
reintervention
Cumulative incidence of re-laparotomy Reoperation in the abdominal region
In-hospital use of antibiotics Defined as “days on therapy”
6 months after surgery
All-cause mortality
Quality of life Measured with the RAND-36 questionnaire [39]
Length of hospital stay In days, including all readmissions
Length of ICU stay In days, including all readmissions
In-hospital costs
CDC Centers for Disease Control and Prevention, ESBL extended-spectrum beta-lactamase, HRE highly resistant Enterobacteriaceae, ICU intensive care unit, SSI surgical
site infection
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Statistical analysis
The primary composite endpoint will be analyzed
according to the intention-to-treat principle. All patients
who were randomized to receive study medication and
who underwent colorectal surgery will be included in this
analysis. The difference in the primary outcome between
Pre-OP and placebo will be estimated with a Z-test for
proportions or by logistic regression, correcting for the
stratification variable (study site). Multivariable logistic
regression will be used and measured confounders will be
fitted in the model as covariates. Secondary outcomes will
be analyzed using the chi-square test, Fisher’s exact test,
logistic regression, time-to-event analysis, t test or Mann–
Whitney U test, when appropriate. Missing data will be
analyzed and handled using.
Exploratory subgroup analyses will be performed for
study center, age, sex, Body Mass Index (BMI), ASA
classification, preoperative use of immunosuppressive
drugs, preoperative radiation of the surgical site, indica-
tion for surgery, wound class, surgical procedure,
Table 3 Study flow
Study period
Screeningb Enrollmentb Intervention Follow-up and
postoperative procedurescday
Time pointa ~ − 2 weeks ~ − 2 weeks to day − 4 −3 −2 −1 Day 0 Day 30 Month 6
Patient recruitment X
Eligibility screening X
Informed consent X
Allocation X
Rectal swab X X
Intake study medication X X X
Surgery X
Estimation of compliance X X X
Patient characteristics X X
Surgical characteristics X
Primary endpoint Deep SSI and/or mortality X
Secondary endpoints
Superficial SSI X
Anastomotic leakage X
Re-laparotomy X
Bacteremia X
Rectal colonization with HRE or colistin resistant species X
Infection with HRE X
Infection with Clostridium difficile X
In-hospital antibiotic use X
Length of hospital stay X
Length of ICU stay X
All-cause mortality X X
In-hospital costs X
Quality of life X X
Adverse events X X X X X X X
Serious adverse events X X X X X X X
SUSARs/SARs X X X X
HRE highly resistant Enterobacteriaceae, ICU intensive care unit, SAR serious adverse reaction, SSI surgical site infection, SUSAR serious unexpected adverse reaction
aThe day of surgery is referred to as day 0. The exact time points of the first and second preoperative visits to the outpatient clinic will depend on the local
schedules and procedures
bScreening and enrollment are performed during visits to the outpatient clinic. These visits are not study-specific and are planned according to the local logistics
cThe postoperative data collection is performed by assessment of the patient registers. A phone call will be made at around day 30 and month 6 to assess the
status of the patient and to remind the patient to perform the rectal swab (day 30) and fill in the questionnaire (month 6)
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duration of surgery and timing of perioperative intraven-
ously administered antibiotic prophylaxis. Per-protocol
analyses will be performed in addition to all the
intention-to-treat analyses.
Interim analysis
One interim analysis will be performed when 50% of the
participants completed the 30-day follow-up. The Z-
statistic for the standardized treatment effect will be
computed and compared with the O’Brien-Fleming type
of boundaries for both efficacy and futility. Recruitment
will stop if the Z statistic is larger than the efficacy
boundary. The futility boundaries are non-binding and
thus suggestive. The unblinded results of the interim
analysis will be presented to an independent Data Safety
and Monitoring Board (DSMB).
Monitoring and safety
Independent Good Clinical Practice (GCP)-certified
monitors from the UMC Utrecht will monitor the data
collection and study progress. The frequency of these
visits will be on a risk-based approach according to GCP
guidelines.
Data entry will be verified using internal monitoring
by a member of the coordinating study team. In
addition, external monitoring will be performed by the
independent monitors. During the monitoring visit, data
entry will be verified on a random sample of the in-
cluded patients by assessment of the source documents
(e.g., electronic patient files, questionnaires or diaries).
In the case of discrepancies or missing data, queries will
be added to the questions that need revision or add-
itional information.
Adverse events
Pre-OP consists of non-absorbable antibiotics. When
taken orally, there is virtually no uptake of antibiotic
components in the bloodstream. It is, therefore,
expected that the occurrence of systemic side effects is
negligible. More importantly, there is extensive experi-
ence with non-absorbable antibiotics applied as SDD on
ICUs and severe and acute side effects that could apply
to the current study have not been reported [27–30].
For this reason, we decided to refrain from an obligatory
observation period after intake of the first dose of the
study medication and patients can, therefore, take the
medication at home. Nevertheless, patients will receive
information about severe side effects of this study medi-
cation and are instructed to seek medical advice when
they might suffer from severe acute side effects. The
unblinding protocol can be freely assessed via our website,
when deemed necessary. Late side effects, such as the
development of antibiotic resistance, have not been
described either [31–35]. Nevertheless, the occurrence of
side effects and the development of antibiotic resistance
will be monitored as secondary endpoints of this study.
All adverse events will be reported to the principle
investigator. Serious adverse events (SAEs), serious ad-
verse reactions (SARs) and suspected unexpected serious
adverse reactions (SUSARs) will be reported to the
sponsor within 24 h after notification of the event. For
the SAEs, we decided to only report life-threatening in-
fections with colistin- or tobramycin-resistant bacteria
or C. difficile colitis within 24 h. Postoperative complica-
tions that are known to occur after colorectal surgery
and are not directly related to the study medication will
be reported to the ethical board in periodic line-listings
and not within the 24-h time window.
Data Safety and Monitoring Board
A Data Safety and Monitoring Board (DSMB) is estab-
lished to guard patient safety during the trial. The
DSMB consists of four independent experts who will
have an active role during the entire study period. The
board will issue recommendations to continue or stop
the study, based on the unblinded results of the interim
analysis and on the list of SAEs, SARs and SUSARs.
Discussion
Undergoing surgery is associated with an increased risk
of surgical site infections, but also mortality. To over-
come the issue of mortality being a competing risk with
the development of deep SSIs, our primary outcome of
interest, we decided to use a composite endpoint for our
primary outcome. Thirty-day all-cause mortality and
deep SSIs will also be analyzed separately as secondary
endpoints.
The rationale behind our intervention is to decontam-
inate the digestive tract prior to surgery, where we
hypothesize that by lowering the bacterial load in the
colon and rectum during the surgical procedure, the risk
of postoperative infections is reduced. In a previous
study, a suspension of colistin sulphate, tobramycin and
amphotericin B was used to reduce anastomotic leakage
and postoperative infectious complications [24]. This
suspension is identical to the suspension that is used as
an antibiotic prophylaxis on Dutch ICUs, often referred
to as SDD). In contrast with SDD, the solution that will
be used in our study does not contain an antifungal
component (amphotericin B or nystatin). Fungi are
rarely identified as the causative pathogens of SSIs after
surgical procedures on the lower gastrointestinal tract
and it was, therefore, decided to omit the antifungal
component [36]. Another difference between our study
and the trial by Roos et al. is the timing of the treatment.
In the previous trial, the intervention started 2 days
prior to surgery and was continued during the postoper-
ative period until normal bowel movements were
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observed. In our study, the intervention will only be
given preoperatively and is discontinued on the night be-
fore the surgical procedure. We hypothesize that the
majority of SSIs is caused by intraoperative rather than
postoperative contamination of the surgical site and that
the greatest reduction in SSIs will, therefore, be achieved
by ensuring that the colonic bacterial load is at its lower-
most at the time the surgical procedure takes place. The
prophylaxis in our study is, therefore, restricted to the
preoperative period. We also hypothesize that the treat-
ment period of 3 days will be sufficient since we expect
that the decontamination will least for several days. In
our opinion, continuation of the prophylaxis in the post-
operative period is not necessary as this could adversely
increase the risk of developing antibiotic resistance or
opportunistic infections.
To date, there is no consensus on the use of preopera-
tive orally administered antibiotic prophylaxis prior to
colorectal surgery in addition to perioperative intraven-
ously administered antibiotic prophylaxis and without
concurrent use of MBP. This impedes the formulation of
clear-cut recommendations on its use in current infection
control guidelines. This randomized, placebo-controlled,
double-blind multicenter study aims to determine the effi-
cacy of Pre-OP in addition to perioperative intravenously
administered antimicrobial prophylaxis on the develop-
ment of SSIs and other infectious and non-infectious
complications. The proposed study design offers an opti-
mal approach to adequately minimize bias and generate
generalizable results in order to guide important
evidence-based recommendations regarding infection
control measures in colorectal surgery (Additional file 2).
Trial status
The trial received ethical approval in September 2016.
The recruitment of patients started in April 2017.
Additional files
Additional file 1: Case Report Form. (DOCX 42 kb)
Additional file 2: SPIRIT 2013 Checklist used as a guideance for the
development of the PreCaution study protocol. (DOC 120 kb)
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